<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433563</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000531709</org_study_id>
    <secondary_id>CHNT-CONVERT</secondary_id>
    <secondary_id>CHNT-CTAAC-CONVERT-C17052/A815</secondary_id>
    <nct_id>NCT00433563</nct_id>
  </id_info>
  <brief_title>Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer</brief_title>
  <acronym>CONVERT</acronym>
  <official_title>A 2-Arm Randomized Controlled Trial of Concurrent Chemo-Radiotherapy Comparing Twice-Daily and Once-Daily Radiotherapy Schedules in Patients With Limited Stage Small Cell Lung Cancer (SCLC) and Good Performance Status [CONVERT]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Lung Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Francais De Pneumo-Cancerologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Christie NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known&#xD;
      which schedule of radiation therapy is more effective when given together with chemotherapy&#xD;
      in treating small cell lung cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying two different schedules of radiation&#xD;
      therapy to compare how well they work when given together with cisplatin and etoposide in&#xD;
      treating patients with limited stage small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare overall survival of patients with limited stage small cell lung cancer treated&#xD;
           with chemoradiotherapy comprising cisplatin, etoposide, and once vs twice daily&#xD;
           radiotherapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare local progression-free survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare metastasis-free survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Compare response rates in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the cytotoxic dose intensity of these regimens in these patients.&#xD;
&#xD;
        -  Compare the dose intensity of two different schedules of radiotherapy in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, randomized, controlled study. Patients are stratified&#xD;
      according to participating center, ECOG performance status (0-1 vs 2), and lactic&#xD;
      dehydrogenase, sodium, and alkaline phosphatase levels. Patients are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive cisplatin IV over 2 hours on days 1-3 OR on day 1 only and&#xD;
           etoposide IV over 45-90 minutes on days 1-3. Treatment repeats every 21 days for up to 6&#xD;
           courses. During course 2, patients undergo concurrent radiotherapy once daily 5 days a&#xD;
           week for 6½ weeks (total of 33 fractions).&#xD;
&#xD;
        -  Arm II: Patients receive cisplatin and etoposide as in arm I. During courses 2 and 3,&#xD;
           patients undergo concurrent radiotherapy twice daily 5 days a week for 3 weeks (total of&#xD;
           30 fractions).&#xD;
&#xD;
      In both arms, treatment continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Beginning 3-4 weeks after completion of chemoradiotherapy, patients in both arms achieving a&#xD;
      complete or partial response with no evidence of brain metastasis undergo prophylactic&#xD;
      cranial irradiation once daily 5 days a week for 2 weeks (total of 10 fractions).&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year, every 6&#xD;
      months for 2 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 532 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>August 2015</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local progression-free survival</measure>
    <time_frame>August 2015</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival</measure>
    <time_frame>August 2015</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>August 2015</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytotoxic dose intensity</measure>
    <time_frame>August 2015</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy dose intensity</measure>
    <time_frame>August 2015</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">547</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Once daily radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twice daily radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twice daily radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Once daily radiotherapy</intervention_name>
    <description>Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy</description>
    <arm_group_label>Once daily radiotherapy</arm_group_label>
    <arm_group_label>Twice daily radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Twice daily radiotherapy</intervention_name>
    <description>Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy</description>
    <arm_group_label>Once daily radiotherapy</arm_group_label>
    <arm_group_label>Twice daily radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion/exclusion criteria:&#xD;
&#xD;
          -  Either sex, age ≥18 years&#xD;
&#xD;
          -  Performance status ECOG grade 0-1. Patients with PS 2 whose general condition is&#xD;
             explained by obstructive/bulky disease likely to improve after the first cycle of&#xD;
             chemotherapy can be included at the discretion of the local investigator. Patients&#xD;
             with PS 2 as a result of comorbid conditions will be excluded.&#xD;
&#xD;
          -  Histologically or cytologically confirmed SCLC&#xD;
&#xD;
          -  No patients with mixed small-cell and non-small-cell histologic features&#xD;
&#xD;
          -  No history of previous malignancy in the last 5 years (except non melanomatous skin or&#xD;
             in-situ cervix carcinoma). Patients with previous malignancies (except breast cancer)&#xD;
             and in remission for at least 5 years can be included.&#xD;
&#xD;
          -  Limited stage disease (Veterans Administration Lung Cancer Study Group) ie patients&#xD;
             whose disease can be encompassed within a radical radiation portal.&#xD;
&#xD;
          -  No pleural or pericardial effusions proven to be malignant&#xD;
&#xD;
          -  RT target volume acceptable by the local radiotherapist&#xD;
&#xD;
          -  Pulmonary function&#xD;
&#xD;
               1. FEV1 &gt;1 litre or 40% predicted value&#xD;
&#xD;
               2. KCO (DLCO/VA) &gt;40%predicted&#xD;
&#xD;
          -  Maximum of one of the following adverse biochemical factors:&#xD;
&#xD;
               1. Serum alkaline phosphatase more than &gt;1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
               2. Serum sodium &lt; Lower limit of Normal&#xD;
&#xD;
               3. Serum LDH &gt; ULN&#xD;
&#xD;
          -  Normal serum creatinine and calculated creatinine clearance &gt;50 ml/min. If calculated&#xD;
             creatinine clearance is &lt;50 ml/mn according to the Cockroft and Gault formula, an EDTA&#xD;
             clearance should be performed&#xD;
&#xD;
          -  Adequate haematological function&#xD;
&#xD;
               1. Neutrophils &gt;1.5 x 109/l&#xD;
&#xD;
               2. Platelets &gt;100 x 109/l&#xD;
&#xD;
          -  Adequate liver function: ALT &amp; AST &lt;= 2.5 x ULN&#xD;
&#xD;
          -  No other previous or concomitant illness or treatment which in the opinion of the&#xD;
             clinician will interfere with the trial treatments or comparisons&#xD;
&#xD;
          -  No prior surgical resection of the primary tumour, no prior radiotherapy for lung&#xD;
             cancer&#xD;
&#xD;
          -  Considered fit to receive any of the trial regimens&#xD;
&#xD;
          -  Female patients must satisfy the investigator that they are not pregnant, or are not&#xD;
             of child-bearing potential, or are using adequate contraception. Men must also use&#xD;
             adequate contraception, as etoposide is clastogenic.&#xD;
&#xD;
          -  Patients must not be breastfeeding&#xD;
&#xD;
          -  Patient has read the patient information sheet and has signed the consent form.&#xD;
&#xD;
          -  Patients available for follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne Faivre-Finn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 8, 2007</study_first_submitted>
  <study_first_submitted_qc>February 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>limited stage small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

